Dermatology Update 2017 Fall
SESSIONS & ABSTRACTS
VANCOUVER, FAIRMONT WATERFRONT HOTEL - OCTOBER 26-29, 2017
PDE-4 inhibition for Psoriasis: From clinical trial, to clinician experience, to patient experience
Dr Jensen Yeung will
- briefly review the safety and efficacy outcomes of current clinical trials
- highlight new real world safety and efficacy data
- explore observational study data which highlights the role of the patient in defining successful treatment
Psoriasis is a common chronic immune mediated disease of the skin. Many patients experience a significant negative impact on physical, emotional, and psychosocial wellbeing. Not all patients respond to traditional topical and systemic treatments. Phototherapy or biological agents may not be suitable for some patients.
Apremilast, an oral phosphodiesterase 4 inhibitor, modulates inflammatory signaling pathways associated with signs and symptoms of plaque psoriasis.
Randomized clinical trials ESTEEM 1 and 2, demonstrated its safety and efficacy in patients with moderate-to-severe psoriasis.
This plenary will look beyond phase 3 clinical trial data, and discuss data from real world clinical experience in 2 academic centers at the University of Toronto to inform dermatologists of the practicalities of using an oral targeted systemic therapy. Patient experience and preferences will be highlighted to further understand the value of newer therapies available in the psoriasis treatment tool box.